Talvey (talquetamab-tgvs) / J&J, Genmab - LARVOL DELTA

MRD-Guided Frontline T-Cell Redirection Therapy for Newly Diagnosed High-Risk Multiple Myeloma Using Teclistamab-Daratumumab Intensification and Talquetamab-Daratumumab Early Rescue Intervention (IMS 2026) - P2 | "To evaluate the safety and preliminary efficacy of teclistamab-daratumumab (Tec-D) intensification following daratumumab-bortezomib-lenalidomide-dexamethasone (D-VRd) induction in ND-HRMM...CRS occurred in 7 patients (25%), all grade 1; only one required tocilizumab... Early MRD-guided incorporation of Tec-D intensification induced deep responses and high MRD-CR in ND-HRMM, supporting the evaluation of a full-immune based bispecific antibody-based, transplant-free approach in difficult to treat high-risk disease."

Late-breaking abstract • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Pneumonia • Respiratory Diseases

Treatment Naive GPRC5D Negative Multiple Myeloma With t(11;14) (IMS 2026) - P1 | "Clinical validation was performed in 32 RRMM patients enrolled in two anti-GPRC5D CART trials (NCT04555551, NCT05431608) and 117 patients treated with Talquetamab...As additional validation, in the Talquetamab cohort (n=117), patients with t(11;14) and prior Venetoclax sensitivity showed no GPRC5D expression and primary refractoriness to anti-GPRC5D... This study identifies a strong association of GPRC5D negativity with a t(11;14), B-cell-like profile, and genomically indolent myeloma subgroup, potentially conferring refractoriness to anti-GPRC5D therapy. As this group accounts for 10% of NDMM, and GPRC5D protein measurement can be performed by IHC, this represents a feasible and accessible biomarker for immunotherapy selection in myeloma. Importantly, these patients usually have a genomically indolent profile and are particularly sensitive to anti-BCMA therapies (Maura et al."

IO biomarker • Hematological Malignancies • Multiple Myeloma • CD2 • GPRC5D • TP53

Teclistamab Plus Talquetamab Consolidation in Newly Diagnosed Myeloma Patients With Positive Measurable Residual Disease After DVRD Induction : Interim Analysis of the Phase 2 Study IFM 2022-01 (IMS 2026) - P2 | "IFM 2022-01 is a phase 2 trial evaluating tec plus tal or tec plus lenalidomide consolidation in TE-NDMM patients according to measurable residual disease (MRD) after Daratumumab Bortezomib Lenalidomide Dexamethasone (D-VRd) induction. The combination of tec+tal resulted in early and high undetectable MRD rates in NDMM patients with detectable MRD after D-VRD induction. These preliminary data showed no new safety signal was observed with tec+tal used in frontline."

Clinical • P2 data • Residual disease • Hematological Malignancies • Infectious Disease • Multiple Myeloma

Matching-Adjusted Indirect Comparisons (MAICs) of Anitocabtagene Autoleucel (Anito-Cel) Versus Teclistamab and Talquetamab for the Treatment of 4L+ Relapsed And/or Refractory Multiple Myeloma (RRMM) (IMS 2026) - "Anito -cel showed superior response, and a differentiated safety profile versus TEC and TAL, highlighted by lower odds of any-grade ICANS versus TAL, and high-grade infections/NRM across all comparators, supporting a clinically meaningful benefit–risk advantage compared to BCMA and GPRC5D targeting BsAbs in 4L+ RRMM."

Hematological Malignancies • Infectious Disease • Multiple Myeloma

Treatment-Naïve GPRC5D-Negative Multiple Myeloma With t(11;14) (IMS 2026) - P1 | "Clinical validation was performed in 32 RRMM patients enrolled in two anti-GPRC5D CART trials (NCT04555551, NCT05431608) and 117 patients treated with Talquetamab...As additional validation, in the Talquetamab cohort (n=117), patients with t(11;14) and prior Venetoclax sensitivity showed no GPRC5D expression and primary refractoriness to anti-GPRC5D... This study identifies a strong association of GPRC5D negativity with a t(11;14), B-cell-like profile, and genomically indolent myeloma subgroup, potentially conferring refractoriness to anti-GPRC5D therapy. As this group accounts for 10% of NDMM, and GPRC5D protein measurement can be performed by IHC, this represents a feasible and accessible biomarker for immunotherapy selection in myeloma. Importantly, these patients usually have a genomically indolent profile and are particularly sensitive to anti-BCMA therapies (Maura et al."

IO biomarker • Hematological Malignancies • Multiple Myeloma • CD2 • GPRC5D • TP53

UK Expert Delphi Consensus on Managing Talquetamab-Associated Oral Side Effects and Weight Loss in Patients With Multiple Myeloma (IMS 2026) - "Given the limited evidence, this UK Delphi provides consensus recommendations to recognise, monitor and manage talquetamab-associated oral side effects and weight loss. Priorities include early risk assessment, patient-centered education, individualised dietary strategies and clear pathways for dietary support. The recommendations provide a framework for clinical practice, as talquetamab use expands in routine care."

Adverse events • Clinical • Dental Disorders • Hematological Malignancies • Multiple Myeloma • Stomatitis • Xerostomia

Timing and Resolution of Talquetamab-Related Dysgeusia in Relapsed/Refractory Multiple Myeloma (RRMM): Longitudinal Waterless Empirical Taste Test and Patient Reported Outcomes Profiles from Talisman (IMS 2026) - P2 | "Introduction: In MonumenTAL-1, talquetamab (Tal) elicited durable responses in patients (pts) with RRMM. Dysgeusia by WETT improves as early as 3 months after Tal initiation, with 67% showing improvement after 7 months. Clonazepam prophylaxis did not improve incidence, onset, or resolution of dysgeusia, although low numbers limit definitive conclusions. The highest proportion of pts with dysgeusia/severe dysgeusia by WETT occurred during cycle 3, with the largest changes observed in the sweet, salty, and sour components of the taste profile."

Clinical • Patient reported outcomes • Hematological Malignancies • Multiple Myeloma

Phase 3, Randomized Study of Talquetamab (Tal) Plus Daratumumab (D) ± Pomalidomide (P) vs D Plus P and Dexamethasone (DPd) in Relapsed/Refractory Multiple Myeloma (RRMM): MonumenTAL-3 (IMS 2026) - P3 | " Phase 3 study randomizing pts with RRMM and ≥1 prior LOT including lenalidomide (R) and a proteasome inhibitor 1:1:1 to Tal-DP, Tal-D, or DPd. Tal-DP and Tal-D demonstrated a significant PFS benefit vs DPd, clinically meaningful OS improvements and gr ≥3 infection rates similar to or lower than DPd. Tal was combinable, with low rates of tx d/c. Tal-D ± P represents a new standard of care for RRMM as early as 2L across all practice settings."

Clinical • P3 data • Ataxia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Movement Disorders • Multiple Myeloma • Otorhinolaryngology

Treatment Patterns and Outcomes in Primary Plasma Cell Leukemia: A Single-Center Case Series (IMS 2026) - "Two patients (18%) developed progressive disease, of whom one received talquetamab as a bridge to CAR-T cell therapy...Improved survival of patients with primary plasma cell leukemia with VRd or daratumumab-based quadruplets: a multicenter study by the Greek Myeloma Study Group. In this retrospective review of pPCL, DQ regimens were universally incorporated into therapy. ASCT was performed in the majority of patients. Updated disease status will be provided at the time of conference."

Clinical • Hematological Malignancies • Leukemia • Plasma Cell Leukemia • Plasmacytoma • B2M

TARGET-LATAM Targeted Bispecific Antibodies Against BCMA and GPRC5D in Relapsed/Refractory Multiple Myeloma a Real-World Comparative Analysis from the GELAMM Group (IMS 2026) - "In this Latin American cohort of heavily pretreated RRMM patients, anti-BCMA (teclistamab/elranatamab) and anti-GPRC5D (talquetamab) bispecific antibodies demonstrated comparable efficacy in PFS and OS after propensity score matching. However, anti-BCMA therapy was associated with significantly higher rates of any-grade infectious toxicity (p < 0.001) and hypogammaglobulinemia < 400 mg/dL (p = 0.013), underscoring the importance of close infectious-disease monitoring and immunoglobulin replacement strategies in this population."

Bispecific • Clinical • Real-world • Real-world evidence • Hematological Malignancies • Infectious Disease • Multiple Myeloma

Systematic Review and Meta-Analysis of Tocilizumab Prophylaxis for Cytokine Release Syndrome (CRS) in Bispecific Antibody Therapy for Multiple Myeloma (IMS 2026) - "Databases (PubMed, Cochrane, Embase, Google Scholar) and ClinicalTrials.gov were searched with MeSH terms and keywords for tocilizumab, prophylaxis, CRS, bispecific, teclistamab, talquetamab, elranatamab, linvoseltamab, cevostamab, and multiple myeloma. A single prophylactic dose of tocilizumab before the first step-up dose consistently and substantially reduces CRS — to a pooled 9% with almost absence of grade ≥3 events. This low rate of CRS with prophylactic tocilizumab could lend to safe adoption of bispecifics in academic and community practices."

Bispecific • Cytokine release syndrome • Retrospective data • Review • Hematological Disorders • Hematological Malignancies • Infectious Disease • Inflammation • Multiple Myeloma • Neutropenia

Shifting Landscapes in Triple-Class Exposed Multiple Myeloma in Latin America (LATAM): Real-World Outcomes with Bispecific Antibodies Versus Standard of Care (IMS 2026) - "Pts receiving BsAbs (teclistamab, talquetamab, or elranatamab) were compared with those treated with standard-of-care (SoC)-based salvage regimens. Belantamab mafodotin-treated pts were excluded from the primary comparative analysis due to limited sample size and retained for descriptive purposes only. SoC regimens were grouped as carfilzomib-based, pomalidomide-based, carfilzomib plus pomalidomide-based, chemotherapy-based, and other regimens... In this large real-world LATAM cohort of TCE-RRMM pts, BsAbs were associated with significantly improved response rates and survival outcomes compared with SoC, despite a population enriched with higher refractory burden and EMD prevalence. These findings support the effectiveness of BsAbs in routine clinical practice across LATAM and reinforce the importance of expanding access to novel immunotherapeutic strategies in the region."

Bispecific • Clinical • Real-world • Real-world evidence • Hematological Malignancies • Multiple Myeloma

Severe Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) During Talquetamab Treatment in Relapsed/Refractory Multiple Myeloma: A Case Report (IMS 2026) - "Third-line teclistamab resulted in primary refractory disease, with progression characterized by increased lytic lesions, cortical bone disruption, bulky soft tissue plasmacytomas, and extensive skeletal involvement...She received tocilizumab (8 mg/kg) and dexamethasone (10 mg every 6 hours, with complete CRS resolution within 12 hours... This case highlights a rare but potentially severe neurological complication associated with talquetamab. Early recognition and timely management of ICANS are crucial to minimize neurological complications, improve patient outcomes, and allow safe continuation of therapy, particularly in heavily pretreated elderly patients with complex clinical presentations."

Case report • Clinical • Hematological Malignancies • Hypotension • Multiple Myeloma • Musculoskeletal Diseases • Orthopedics • Plasmacytoma

Selinexor, Mezigdomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Relapsing / Ineligible for T-Cell-Redirecting Therapy (TCRT): STOMP Phase 1 Preliminary Results (IMS 2026) - P1/2 | "Three pts relapsed after TCRT (3 cilta-cel; 2 talquetamab; 1 IGM-2644) and 4 after belantamab mafodotin, with 3 pts refractory to B-cell maturation antigen–targeted therapy. For the SMd all-oral combination, TEAEs were consistent with AE profiles for S and M, and no new safety signals were detected. The DLT of G4 neutropenia was manageable with filgrastim and dose reduction. Across all dose levels SMd showed efficacy in pts with heavily pretreated RRMM in whom TCRT had failed or who could not receive TCRT."

Clinical • IO biomarker • P1 data • Cardiovascular • Constipation • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Leukopenia • Multiple Myeloma • Neutropenia • Targeted Protein Degradation • Thrombocytopenia • CCR7 • CRBN • TIGIT • XPO1

Safety and Feasibility of Outpatient Bispecific Antibodies Step-Up Doses Administration for the Treatment of Relapsed/Refractory Multiple Myeloma: A Real-World Multicenter Study. (IMS 2026) - " Overall, 86 patients (pts) received outpt bsAb SUD (30 teclistamab, 16 elranatamab, 40 talquetamab) in 18 Italian centers (ctr), with a median follow up of 7 (range 1-35) months (m)...Cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome prevention strategies (CRS/ICANS-PS) consisted in per label premedication for all pts; in addition, 26 (30%) received prophylactic tocilizumab (PT), 33 (38%) dexamethasone post medication and 6 (7%) both... Our RW results support outpt bsAb SUD as a safe and viable option with the use of structured protocols, with PT emerging as the most effective strategy to reduce CRS and facilitate SUD completion in this setting."

Bispecific • Clinical • Real-world • Real-world evidence • Hematological Malignancies • Infectious Disease • Inflammation • Multiple Myeloma

Safety and Efficacy of Talquetamab in Multiple Myeloma Patients with Renal Insufficiency (IMS 2026) - "RI did not affect the response to talq in our cohort but was associated with a longer duration of hospitalization to complete ramp-up. RI was also not associated with more adverse events of talq compared to RRMM patients without RI. Larger studies are needed to evaluate the efficacy of BsAbs in RRMM patients with RI; however, RI itself should not be an exclusion to enrollment in these studies."

Clinical • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Nephrology • Renal Disease • Xerostomia

Rethinking Routine IVIG Use with Talquetamab in Relapsed/Refractory Multiple Myeloma (IMS 2026) - "In this multicenter real-world cohort, infections during TAL therapy were common were often early, recurrent, and frequently required hospitalization. Early IVIG was not associated with reduced first infection risk, but the trend toward fewer later hospitalization-associated infections suggests potential utility in selected higher-risk patients rather than as a routine prophylaxis for all. Prior BCMA exposure did not increase first infection risk."

Hematological Malignancies • Infectious Disease • Multiple Myeloma

Response to Bispecifics in Relapsed-Refractory Multiple Myeloma (RRMM) Patients with Severe Renal Insufficiency: Case Series (IMS 2026) - "Teclistamab (Tec) and talquetamab (Tal) are approved for relapsed-refractory multiple myeloma (RRMM); however, patients with pre-treatment creatinine clearance (CrCl) less than 40 mL/min were excluded...Five patients received Tec only, one received Tal only, two received both agents separately, and one received Tec plus daratumumab...Additionally, all patients received tocilizumab 8 mg/kg (capped at 800 mg) once prior to step-up dose 1 for cytokine release syndrome (CRS) prophylaxis in accordance with the institutional standard... Tec and Tal were well tolerated in RRMM patients with CrCl < 40mL/min. Patients with renal insufficiency should not be excluded from getting BsAbs."

Bispecific • Clinical • Hematological Malignancies • Infectious Disease • Inflammation • Multiple Myeloma • Nephrology • Renal Disease

Real-World Outcomes and Predictors of Bispecific Antibody Therapy Response in a Racially Diverse Multiple Myeloma Cohort (IMS 2026) - " Median age 69 yr; 32% Black; 42% high-risk cytogenetics; 29% extramedullary disease (EMD); median 4 prior lines of therapy; 84% BCMA-directed, and 16% talquetamab as first bispecific therapy... In a racially diverse real-world RRMM cohort, BsAbs achieved efficacy and safety comparable to pivotal-trial benchmarks across races despite higher-risk biology. EMD was the dominant adverse PFS predictor; CRS was a positive independent factor, suggestive of CRS as a marker of on-target T-cell activation. Black patients had markedly higher growth-factor utilization without excess infection or mortality, suggesting that optimized supportive-care strategies may help mitigate disparities in patients receiving BsAbs."

Bispecific • Clinical • IO biomarker • Real-world • Real-world evidence • Hematological Malignancies • Infectious Disease • Multiple Myeloma

Real-World Experience with Teclistamab and Talquetamab Combination Therapy in Relapsed/Refractory Multiple Myeloma (IMS 2026) - "Introduction: Combination therapy with teclistamab and talquetamab (tec/tal) is an effective option for patients with relapsed/refractory multiple myeloma (Cohen et al., NEJM 2025). In this single-center real-world experience study with tec/tal, no new safety signals were identified among a heavily pretreated cohort of patients despite poor PS and presence of EMD. Surprisingly, when taken in the context of tec/tal clinical trial data, no infectious complications were observed. The lack of infections may reflect improved infectious prophylaxis with IVIG independent of IgG levels and levofloxacin for all patients for at least one month."

Clinical • Combination therapy • Real-world • Real-world evidence • Hematological Malignancies • Infectious Disease • Multiple Myeloma

Real-World Efficacy and Safety?Outcomes of Talquetamab: An Updated Analysis in Predominantly Community-Based Setting (IMS 2026) - "In this real world study conducted primarily in US community settings, TAL demonstrated meaningful clinical activity with robust response rates and encouraging survival estimates in the overall population as well as the USPI cohort. Most pts remained on TAL with low rates of AE-related discontinuation. These findings support the effectiveness of TAL in routine clinical practice and highlight the value of continued follow up to further characterize long term outcomes."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Hematological Malignancies • Multiple Myeloma

Real-World (RW) Characteristics, Treatment Patterns, and Outcomes in Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM) in Europe: Results from the HARMONY Big Data Platform (IMS 2026) - "Overall, 92% (n=458) were exposed to daratumumab, with 87% first receiving it in 2L and 5% in 1L...In the 3L cohort (n=152), >40 unique regimens were used; top regimens were carfilzomib-dexamethasone (dex) (16%), pomalidomide-dex (14%), and bortezomib-pomalidomide-dex (11%). Across the 2020+ subgroup (N=415), utilization of BsAbs in index LoT was low: teclistamab (18 [4%]), talquetamab (8 [2%]), elranatamab (2 [ < 1%])... European RW data, primarily from the Czech Republic, show fragmented treatment patterns for 3L+ TCE RRMM. Pts relapse quickly and survival worsens with later LoT. Despite the approval of novel immunotherapies, RW uptake remains limited and outcomes continue to be poor, highlighting the need for more effective and broadly accessible therapies."

Clinical • Real-world • Real-world evidence • Hematological Malignancies • Multiple Myeloma

Prophylactic Tocilizumab to Mitigate Cytokine Release Syndrome and Facilitate Dosing of Talquetamab in All Practice Settings in Relapsed/Refractory Multiple Myeloma: Results from Monumental-1 (IMS 2026) - "Dexamethasone (dex; 8 mg PO or IV) was given daily for 2 days after each SUD and the first full treatment dose. Use of prophylactic toci with Tal +/- a modified Tal SUD schedule demonstrated a reduction in the incidence and severity of CRS and manageable safety profile. No increase in neutropenia or infection rates was observed. These results may support broader implementation of Tal with toci prophylaxis and postdose dex across all practice settings in pts with RRMM."

Cytokine release syndrome • Hematological Disorders • Hematological Malignancies • Infectious Disease • Inflammation • Multiple Myeloma • Neutropenia • Xerostomia

Preemptive Tocilizumab in Patients with Relapsed-Refractory Multiple Myeloma Receiving Bispecific: A Case Series (IMS 2026) - "Teclistamab (Tec), talquetamab (Tal), and elranatamab (Elra) are bispecific antibodies (BsAbs) approved for relapsed-refractory multiple myeloma (RRMM)...All patients received intravenous immunoglobulin to maintain functional IgG ≥500 mg/dL, filgrastim to maintain absolute neutrophil 1.00 K/mcL, epoetin alfa to maintain hemoglobin above 10 g/dL, and romiplostim to maintain platelets above 50 K/mcL...The only incident of CRS occurred with a single patient who developed grade 1 CRS on C1D3 which resolved after one dose of dexamethasone 10 mg... Preemptive Toci may decrease the incidence and severity of CRS in patients with RRMM receiving BsAbs, without compromising response. In this small observational analysis, no patients experienced prolonged hospitalization for management of CRS."

Bispecific • Clinical • Hematological Malignancies • Infectious Disease • Multiple Myeloma

Outpatient Step-Up Dosing of Teclistamab or Talquetamab with Prophylactic Tocilizumab in Patients with Relapsed/Refractory Multiple Myeloma: Real-World Evidence from a Large US Cancer Center (IMS 2026) - "G1 ICANS was managed with dexamethasone, while G2 was treated with dexamethasone and anakinra per institutional SOP. OP SUD can broaden pt access to Tec and Tal and reduce healthcare resource utilization. OP SUD using prophylactic toci can reduce hospitalization with Tec and Tal while a hybrid model facilitates rapid discharge of pts to complete their treatment in the OP setting. Both strategies facilitate broad medical adoption of Tec and Tal across practice settings."

Clinical • HEOR • Real-world • Real-world evidence • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Oncology • Renal Disease